Loading stock data…
Verastem, Inc. (VSTM)
$8.08-0.12 (-1.46%)
Market ClosedLast close Sep 8
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Verastem, Inc. in the Healthcare sector is trading at $8.08 with a market capitalization of $596M. Wall Street consensus targets $15.00 (8 analysts), implying a +85.6% move over the next 12 months. The stock is currently 25% below its 52-week high of $10.82, remaining 29.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +85.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $40.08M↑ | $18.67M↑ | $17.54M↑ | $11.24M↑ | $2.14M |
| Gross Profit | $36.04M↑ | $15.62M↑ | $14.64M↑ | $9.28M↑ | $1.69M |
| Operating Income | -$32.71M↑ | -$44.90M↓ | -$41.48M↓ | -$40.72M↑ | -$43.76M |
| Net Income | -$34.67M↑ | -$36.59M↓ | -$32.92M↑ | -$98.52M↓ | -$25.93M |
Peer Comparison
JNJUNHPFE
Fundamentals
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$595.91M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.29
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-405.51%
Volume
Today's trading volume
4.37M
Recent News
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
VSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances across key cancer studies.
Verastem (VSTM) Stock Sees Fair Value Moves Lower As Analysts Cut Revenue Views
The average assessed fair value for Verastem has been cut from $16.13 to $14.75, pointing to a moderate reset in price targets. Analysts link this change to a more cautious stance on competition and revenue assumptions, even as many still focus on how Verastem executes on its pipeline and upcoming catalysts. As you read on, you will see how these shifting targets fit into the broader analyst narrative and what to watch as it evolves. Analyst Price Targets don't always capture the full story...
Verastem (VSTM) Q2 2026 Earnings Call Transcript
Revenue surged on CO-PACK launch as cash runway extends into late 2027.
Verastem Q2 Earnings Call Highlights
Verastem (NASDAQ:VSTM) reported second-quarter 2026 net product revenue of $25.1 million from sales of its AVMAPKI FAKZYNJA CO-PACK, as the company said increased new patient starts, refills and physician adoption supported a rebound in commercial performance. The company also reported $15 million
Verastem Inc (VSTM) (Q2 2026) Earnings Call Highlights: Strong Revenue Rebound and Strategic ...
Verastem Inc (VSTM) reports $25.1 million in Q2 net product revenues, secures non-dilutive financing, and progresses its KRAS G12D inhibitor program with promising clinical data.